Ritobegron clinical trials
Counted the way a researcher would: Ritobegron with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses ritobegron is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
2 studies that test it; most in 2003 (1)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Kissei Pharmaceutical Co., Ltd. (3) · Boehringer Ingelheim (2)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Beta-3 agonists source
- Ritobegron ethyl is a prodrug of it, counted here with related medicines source
Studies
Open first, then newest update. How each study uses ritobegron is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study to Investigate the Regional Drug Absorption of KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02259920Written as KUC 7483 CL, particulate formulationHow we know
- Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of KUC 7483 CL Tablets in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02259764Written as KUC 7483 CL - single rising doseHow we know
- A Confirmatory Study of KUC-7483 in Patients With Overactive BladderCompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT01004315Written as KUC-7483How we know
- Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive BladderWithdrawnPhase 3Kissei Pharmaceutical Co., Ltd.NCT01003405Written as KUC-7483How we know
- A Phase II Study of KUC-7483 in Patients With Overactive BladderCompletedPhase 2Kissei Pharmaceutical Co., Ltd.NCT00742833Written as KUC-7483How we know
Codes
What other systems call ritobegron · ClinicalTrials.gg INT006177
- MeSH (NLM) C576374ritobegronConfirmed NLM, Wikidata
- UNII (FDA) LD86RKR53MRITOBEGRONConfirmed FDA, NLM, Wikidata
- Wikidata Q27282934ritobegronConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C87677RitobegronOne source FDA
- DrugBank DB12080One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C576374 | ritobegron | Confirmed NLM, Wikidata |
| UNII (FDA) | LD86RKR53M | RITOBEGRON | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27282934 | ritobegron | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C87677 | Ritobegron | One source FDA |
| DrugBank | DB12080 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.